PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

Publication | Closed Access

DOI

263

Citations

References

2015

Year

Alison J. Moskowitz, Heiko Schöder, Joachim Yahalom, Susan J. McCall, Stephanie Fox, John F. Gerecitano, Ravinder K. Grewal, Paul A. Hamlin, Steven M. Horwitz, Rachel Kobos,

The Lancet Oncology

Lymphoid NeoplasiaRefractory HodgkinAugmented IfosamideBrentuximab VedotinMedicinePathologyCancer TreatmentImmunotherapyOncologyRadiation OncologyCancer ResearchRadiologyHealth Sciences